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Summary
The ketoreductase (KR) domains eryKR1 and eryKR2
from the erythromycin-producing polyketide synthase
(PKS) reduce 3-ketoacyl-thioester intermediates with
opposite stereospecificity. Modeling of eryKR1 and
eryKR2 showed that conserved amino acids previ-
ously correlated with production of alternative alcohol
configurations lie in the active site. eryKR1 domains
mutated at these positions showed an altered stereo-
chemical outcome in reduction of (2R, S)-2-methyl-3-
oxopentanoic acid N-acetylcysteamine thioester. The
wild-type eryKR1 domain exclusively gave the (2S,
3R)-3-hydroxy-2-methylpentanoic acid N-acetylcyste-
amine thioester, while the double mutant (F141W,
P144G) gave only the (2S, 3S) isomer, a switch of the
alcohol stereochemistry. Mutation of the eryKR2 do-
main, in contrast, greatly increased the proportion of
the wild-type (2R, 3S)-alcohol product. These data
confirm the role of key residues in stereocontrol and
suggest an additional way to make rational alterations
in polyketide antibiotic structure.
Introduction
Modular type I polyketide synthases (PKSs), for example
the 6-deoxyerythronolide B synthase (DEBS) responsi-
ble for synthesis of the aglycone core of the macrolide
antibiotic erythromycin A, are multienzymes that cata-
lyze the assembly line biosynthesis of structurally com-
plex and clinically important polyketide natural products
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C/Juan de la Cierva, N3 Madrid, Spain.[1, 2], starting from simple carboxylic acid building
blocks. Polyketide chain assembly resembles fatty
acid biosynthesis in that acyl-CoA starter units and ex-
tender units are condensed together, without the inter-
mediates being released into solution. In contrast to
fatty acid biosynthesis, modular PKSs utilize a wider va-
riety of starter and extender units, and the b-keto func-
tionality created after each condensation step is not
necessarily fully reduced before the next cycle of chain
extension, leading to a far greater potential for chemical
and stereochemical diversity in the products. A number
of strategies have been successfully used to engineer
modular PKSs, and also downstream post-PKS en-
zymes, to produce rationally altered analogs of bioac-
tive polyketide products [3–7]. In contrast, attempts to
alter the configuration at specific stereocenters have
so far been hampered by our limited understanding of
the fundamental mechanisms by which PKSs exert
stereocontrol over polyketide assembly.
As illustrated in Figure 1 for the first two extension
modules of DEBS, each PKS extension module contains
a ketosynthase (KS) domain, which catalyzes the forma-
tion of a carbon-carbon bond, and an acyltransferase
(AT) domain, which recruits the chain extension unit,
here from (2S)-methylmalonyl-CoA. The acyl carrier pro-
tein (ACP) cooperates in the carbon-carbon bond forma-
tion to form a b-ketoester and then carries the growing
chain to domains involved in reductive processing of
the keto group before the next cycle of chain extension.
These reductive activities are optionally present de-
pending on the module and comprise: a b-ketoreduc-
tase (KR) domain, which catalyzes the reduction of the
initially formed b-ketoester to a b-hydroxyester; a dehy-
dratase (DH) domain, which dehydrates the b-hy-
droxyester; and an enoyl reductase (ER) domain, which
reduces the double bond. There is a good correlation
between the predicted constituent domains and the
chemical structure of the corresponding chain exten-
sion unit in the growing polyketide chain.
The methyl centers at C-2 and the hydroxyl centers at
C-3 can have either an R or S configuration. As first
noted by Celmer, there is a strong position-specific
structural and stereochemical homology in families of
macrolide polyketides, suggesting a genetic origin for
stereochemical control at such centers [8]. AT domains
are not thought [9, 10] to control stereochemistry at
methyl-branched centers in the polyketide product.
Rather, it appears that KS domains in only some exten-
sion modules can catalyze the epimerization, at the
methyl center of the initially formed (2R) isomer of the
ketoester, to the (2S) isomer [11]. If such extension mod-
ules also contain a KR that selects only the (2S) isomer
from the mixture, then, effectively, the KR specificity de-
termines the configuration at the methyl center [12, 13].
The chirality at the b-hydroxyl group is determined by
the direction of hydride addition to the keto group (re or
si face) within the active site of the KR domain. In vivo
studies have shown in a number of cases that swapping
individual KR domains between modules of different
PKSs results in the inversion of alcohol stereochemistry
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278Figure 1. The Stereochemistry of Polyketide
Chain Formation on the First Two Extension
Modules of DEBS, the Erythromycin-Produc-
ing Modular PKS
(A) NADPH-dependent reduction by ketore-
ductase domains eryKR1 and eryKR2 pro-
duces the opposite configuration in the alco-
hol intermediates.
(B) Reduction of a racemic mixture of (2R, S)-
2-methyl-3-oxopentanoic acid N-acetylcys-
teamine ester 1 to four possible diastereo-
isomeric alcohols 2–5. Isomers 2 and 5 are
the expected products from eryKR1 and
eryKR2, respectively, based on the absolute
configuration of erythromycin.
KS, ketosynthase; AT, acyltransferase; KR,
ketoreductase; ACP, acyl carrier protein;
DEBS, 6-deoxyerythronolide B synthase;
NAC, N-acetylcysteamine.at that position in the resulting natural product, indicat-
ing that the stereospecificity of reduction is dictated by
the KR domain and is transferable ([14] and L. Kellen-
berger and P.F.L., unpublished data). However, when a
KR domain in a PKS is presented with an unnatural sub-
strate, the stereochemical outcome may be unexpect-
edly altered [15]. To gain a better understanding of the
factors at work, we have therefore sought to analyze
the intrinsic (stereo)specificity of KR domains.
We have previously shown that the KR activities can
be specifically assayed (as for fatty acid synthases [16,
17]) by using the surrogate substrate (2R, S)-2-methyl-
3-oxopentanoic acid N-acetylcysteamine thioester 1
(Figure 1B), when expressed either as part of a PKS
[13, 15, 18] or as soluble and enzymatically active pro-
teins in recombinant Escherichia coli, in the absence
of other PKS components [19]. In the latter experiments,
eryKR1 was found to be intrinsically both stereoselective
and stereospecific, as it was able to select the expected
(2S) enantiomer from the racemic mixture and make
from it exclusively the expected (2S, 3R)-3-hydroxy-2-
methylpentanoic acid N-acetylcysteamine thioester 2.
The eryKR2 was less active toward 1, and the expected
(2R, 3S)-3-hydroxy-2-methylpentanoic acid N-acetyl-
cysteamine thioester 5 was a minor product; the major-
ity of the product consisted of 3 and 2, obtained by pref-
erential reduction of the ‘‘wrong’’ enantiomer of 1 [19].
These data support the idea that alternative modes of
binding to the KR active site are responsible for different
stereochemical outcomes, and they reveal that the ener-
getic differences between these binding modes are
rather small. Therefore, alteration of a few key residues
at the active site might suffice to induce a change inthe stereochemistry of KR-mediated reduction. There
is clear precedent for this in recent work on two mutually
homologous plant tropinone reductases that act on the
3-keto group of the alkaloid to form two enantiomeric
products, and whose stereospecificity has successfully
been switched by site-directed mutagenesis [20, 21].
It has previously been reported [22, 23] that certain
amino acid residues are characteristic of natural modu-
lar PKS KRs that reduce from one or the other face of a
3-ketoacylthioester substrate. In particular, Caffrey [23]
has noted, among 68 PKS KR domains where the config-
uration of the product is known, 2 amino acid motifs (re-
ferred to here as motif I and motif II, respectively) that are
hallmarks of these 2 groups of enzymes, which he terms
A- and B-side selective (Figure 2). We report here the
site-specific mutagenesis of some of these amino acids
and the effects of these mutations on the stereochemis-
try of the products of KR-mediated ketoreduction by
both eryKR1 and eryKR2. In the absence of an X-ray
crystal structure, we also have undertaken homology
modeling of both eryKR1 and eryKR2 (which, as previ-
ously reported [22], belong to the short-chain dehydro-
genase/reductase [SDR] enzyme family) to analyze for
consistency of active-site architecture and also to eluci-
date whether the residues of the two motifs are situated
close enough to the KR active site that they might plau-
sibly contact the substrate and play a direct role in ste-
reocontrol. Our kinetic and stereochemical analysis
showed that exchange of only two of these amino acids
led to an effective switch of alcohol stereochemistry in
eryKR1. The results of mutation of eryKR2, which is not
stereoselective against diketide substrates, were less
clear-cut, but they also confirmed the importance of
Mutagenesis of Modular PKS Ketoreductases
279Figure 2. Amino Acid Motifs that Are Puta-
tively Involved in the Control of Stereochem-
istry by KR Domains from Modular PKSs
Amino acid motifs have been identified by
Caffrey [23].
(A) The strongest indicator for B-type KR do-
mains is an LDD motif (motif I) in the region
between amino acids 88 and 103, which is
absent from A-type KR domains [22]. Addi-
tional amino acids in the 134–149 region
(motif II), specifically P144 and N148, which
indicate B-type KRs and W141 in A-type do-
mains, support this assignment.
(B) Sequence alignment of KR domains show-
ing the mutants constructed in this work. The
active site motifs, and the changes made, are
indicated in bold (residues are numbered ac-
cording to [23]). The consensus sequences
for A- and B-type KRs are also shown. h, ali-
phatic hydrophobic residue; x, unspecified
residue.these motifs. In an accompanying paper [24] (this issue
of Chemistry & Biology), we demonstrate that the
methods of molecular evolution can be applied to iden-
tify numerous active site mutants of both eryKR1 and
eryKR2 that are active against surrogate substrates,
but which have altered stereocontrol. Making such tai-
lored mutations in KR domains within intact PKS multi-
enzymes would offer a new route to engineered polyke-
tide drugs with altered chirality.
Results and Discussion
Homology Modeling of PKS Ketoreductase Domains
Predicts that Key Amino Acids Proposed
to Be Involved in Stereoselection Are Located
at the Active Site
As previously reported [22], searches of publicly avail-
able databases readily show that the ketoreductase do-
mains of modular PKS multienzymes are members of
the short-chain NAD(P)H-dependent dehydrogenase/
reductase (SDR) enzyme family. These enzymes are
characterized by a well-defined Rossmann fold and by
key tyrosine, serine, lysine, and asparagine residues at
the active site [22, 25]. Homology models of both eryKR1and eryKR2 were constructed based on the SDR enzyme
porcine carbonyl reductase as a template (28% se-
quence identity), as described in Experimental Proce-
dures. The overall fold predicted for eryKR1 and eryKR2
was essentially identical, and served to reveal key con-
served features of their predicted active sites (Figure 3).
The position of the bound NADPH cofactor could also be
modeled with confidence. The carboxyamide group of
the nicotinamide ring of the cofactor is anchored by hy-
drogen bonding to the side chain of S182 in eryKR1
(S181 in eryKR2). This directs the A face of the nicotin-
amide ring toward the putative substrate binding site,
consistent with the observed specificity of both eryKR1
and eryKR2 for hydride transfer of the pro-S hydrogen
from the C-40 of the reduced nicotinamide [26]. The po-
sition of the critical residues Y149 and S136 (Caffrey
numbering [23]), which is thought to assist hydride
transfer by polarization of the keto group of the sub-
strate, is essentially identical in both eryKR1 and eryKR2,
consistent with the idea that the observed differences in
the stereochemistry are determined by different modes
of substrate binding to a conserved catalytic apparatus
[23]. The amino acid sequence motif I [23], containing
the conserved motif LDD at residues 93–95 and also
Chemistry & Biology
280Figure 3. Homology Models of eryKR1 and eryKR2 Indicating the Location of Conserved Amino Acids Proposed to Influence the Stereospec-
ificity of Reduction
In eryKR1, the active site residue Y149 positions the substrate carbonyl for hydride transfer from NADPH (blue). Motif residues are shown in
green as follows: F141, P144, and G148 are part of a loop directly adjacent to catalytic residue Y149, while LDD93–95 belong in a loop adjacent
to the active site. In eryKR2, W141 and 93–95PQQ are the counterparts of F141 and 93–95LDD in eryKR1. The numbering of key residues has
been done to facilitate comparison with Figure 2, based on Caffrey [23]. Because of single amino acid insertions in the sequences of eryKR1
and eryKR2, the true active site residue numbers derived from the model differ very slightly from those shown, and they are given in the Sup-
plemental Data. The coordinates of the homology models are available upon request from the authors.noted by Reid et al. [22], is located in a loop region adja-
cent to the active site Y149 (Figure 3) and to the nicotin-
amide ring of NADPH. The sequence motif II previously
described [23] and including (for eryKR1) residues
F141, P144, and G148 lies in a second loop directly up-
stream of the active site Y149 (Figure 3). This region ap-
parently has no definite secondary structure, but it is
flanked by predicted a helices. In the absence of a crys-
tal structure for a PKS KR domain, these models provide
useful support for the hypothesis that directed muta-
genesis of the motif residues could directly affect ste-
reocontrol by modulating the binding of substrates. Re-
cently, the crystal structure of the discrete KR involved
in biosynthesis of the aromatic polyketide actinorhodin
has been determined [27, 28]. At least for the analogous
KR from the enterocin pathway, it appears that ketore-
duction may take place during polyketide chain elonga-
tion [29]. These enzymes also belong to the SDR family
[23]. Although exact details of substrate-enzyme bind-
ing have proved elusive, inspection of the active site ar-
chitecture also supports the conclusion, from modeling
of the eryKR domains, that motifs I and II are at or near
the active site in such enzymes.
Mutagenesis, Expression, and Relative
Ketoreductase Activities of eryKR1
and eryKR2 Domains
As shown in Figure 2, eryKR1 has LDD at residues 93–95,
as in the motif I consensus for B-type KR domains. In
motif II, the domain lacks W141 and has P144 as ex-
pected [23], but it has G at 148 rather than the consensus
N148. To switch the amino acid residues of the motif to
those typical of A-side KRs, mutant KR1-PQS was
designed to alter all of residues 93–95, and mutant
KR1-WGG was designed to replace F141 and P144 by
W141 and G144 respectively. In a third mutant, KR1-5M, all five amino acid changes were introduced. Exam-
ination of the eryKR2 sequence indicates the absence of
LDD at residues 93–95 and the presence of W141, as ex-
pected for A-type KR domains. In mutant KR2-LDD, res-
idues 93–95 were altered to LDD, and, in an additional
mutant (KR2-LPN), all of W141, A144, and A148 were re-
placed by L141, P144, and N148, respectively. Finally, in
mutant KR2-6M, all six of these amino acid substitutions
were combined. Individual mutant KR domains were ex-
pressed as glutathione-S-transferase (GST) fusion pro-
teins inE. coli, and were purified as previously described
for the wild-type domains [19]. The fusion proteins were
used directly for additional experiments, since we have
previously shown [19] that the presence of the GST do-
main does not affect the kinetics or stereochemistry of
KR-mediated reduction.
In order to assess the effect of the amino acid substi-
tutions on overall KR activity, the rate of consumption of
NADPH was measured at high (presumed to be saturat-
ing) [19] concentrations of both 1 (30 mM) and NADPH
(1 mM) and was compared to the activity of wild-type
KR domains (Figure 4). These data show that substitu-
tions in eryKR1 result in an w5-fold decrease in overall
activity, to a level closer to that of wild-type eryKR2. In
contrast, all of the eryKR2 mutants have a slightly higher
activity than the wild-type domain.
Site-Specific Mutations in Motifs I and II Alter
Stereocontrol by Isolated KR Domains
We next determined the effects of these mutations on
the stereochemical outcome of ketoreduction by sepa-
rating 2–5 from 1 by using chiral HPLC (Figures 5 and
6). Under these conditions, the wild-type eryKR1 domain
produced almost exclusively (>98%) the (2S, 3R) isomer
2 [19] (Figure 5A). Surprisingly, the double mutant al-
tered in motif II (KR1-WGG), although it also showed
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281specificity for the (2S) substrate, reduced it almost ex-
clusively to the (2S, 3S) stereoisomer 3, in which the con-
figuration at C-3 is switched (Figure 5B), together with
very small amounts of both the (2S, 3R) and the (2R,
3R) isomers 2 and 4. The KR1 containing the triple muta-
tion in motif I (KR1-PQS) also favored selection of the
correct stereoisomer of the substrate, but it produced
a 1:1 mixture of 2 and 3, again with a small amount of
4 (Figure 5C), showing that, in this case, reduction oc-
curred without stereochemical preference, from either
face of the keto group. The mutant with all five substitu-
tions (KR1-5M) also showed switched specificity in com-
parison to the wild-type (Figure 5D), yielding almost ex-
clusively the (2S, 3S) stereoisomer 3. None of the eryKR1
mutants in this study showed altered stereoselectivity
since they all preferentially selected the S isomer of 1.
Detailed interpretation of these striking results in
terms of specific enzyme-substrate interactions must
await the determination of the crystal structure of wild-
type and mutant KR domains in the presence of a suit-
able substrate analog. However, these results are con-
sistent with the previously postulated role of conserved
active site residues in determining the stereochemistry
of reduction, as evidenced by sequence alignments of
KR domains [22, 23]. They support the proposal that
the energetic differences between alternative modes of
presentation of 3-oxoacyl-NAC substrates (for example
1) to KR domains are rather small [19]. They also demon-
strate the feasibility of using site-specific mutation to
engineer a precise change in alcohol product stereo-
chemistry.
The consequences of mutation of eryKR2 on the ste-
reocontrol of ketoreduction were less clear-cut (Figure 6).
The wild-type domain under these conditions produces
three products, but the (2S, 3S) isomer 3 and the (2S,
3R) isomer 2 are the predominant forms (Figure 6A). The
Figure 4. Ketoreductase Activity of Recombinant KR Domains
Mutant and wild-type KR domains, purified as their GST fusion pro-
teins, were assayed for NADPH-dependent ketoreductase activity
with (2R, S)-2-methyl-3-oxopentanoic acid NAC ester (IUPAC
name: S-2-acetamidoethyl 3-hydroxy-2-methyl-pentanethioate) 1
as substrate.predicted (2R, 3S) alcohol 5 represents only 6%–15%
of the product mixture [19, 24] (Figure 6A). Presumably,
this lack of expected stereocontrol is a reflection of the
fact that the normal substrate for this enzyme is a trike-
tide rather than a diketide. Unfortunately, the use of
chemically synthesized triketide thioesters as sub-
strates is frustrated by their spontaneous and rapid cy-
clization to the corresponding lactone. Three mutants
of eryKR2 were expressed and assayed. The eryKR2 do-
main containing the triple mutation in motif I (KR2-LDD)
produced only two products, an w1:1 mixture of 3 and
5 (Figure 6B). A similar product mixture was also pro-
duced by the triple mutant in motif II (KR2-LPN) (data
not shown) and by the KR2 with all six substitutions
(KR2-6M) (Figure 6C). These results must be considered
together with the data of Figure 4, showing that the mu-
tant enzymes are apparently more efficient than wild-
type in the NADPH-linked assay. Rather than prompting
the expected switch in the configuration at C-3 of the al-
cohol product, these mutations actually increase the
proportion of the wild-type (2R, 3S) stereoisomer. Again,
in the absence of structural information, no definite inter-
pretation can yet be given for these results. One possible
explanation is that the altered active site disfavors com-
petition from the (2S) enantiomer of substrate 1, and/or
from nonproductive binding modes of the (2R) enantio-
mer. However, as pointed out in the accompanying pa-
per [24], the same alterations in the product ratio are
seen in mutants of eryKR2 where bulky residues (P93 or
W141 or both) are replaced by smaller ones, which would
seem to indicate a more open active site in such mutants.
Whatever the detailed explanation, the present results
confirm the importance of amino acids in motifs I and II
in binding substrate at the active site of KR domains.
They also demonstrate for the first time that mutagenesis
of only a few residues can shift the substrate specificity
of a PKS KR with respect to the configuration at the
methyl-branched (C-2) position of the substrate, as
well as the stereochemistry at C-3.
Several models have been proposed to explain the
stereospecificity of ketoreductases in type I PKS. One
is that the position and orientation of the active site
Y149, which activates the keto group via coordination
of the carbonyl oxygen, is different in A-type and B-
type KR domains, resulting in a different orientation of
reduction [25]. This hypothesis is consistent with the
results of our mutations in the 141–148 (motif II) loop of
KR, which is directly adjacent to the active site tyrosine.
Substitutions in this loop of eryKR1 resulted in switched
specificity, whereas substitutions in the same loop of
eryKR2 resulted in the apparent tightening of the active
site. Both results are consistent with a slight movement
of the active site tyrosine as a result of having to accom-
modate the amino acid substitutions. This model, how-
ever, does not easily explain the effect of substitutions
in the LDD motif I of eryKR1, as these amino acids do
not seem to have any direct contact with the active site
tyrosine in our homology models of KR.
Alternatively, it has been proposed that the active site
architecture is invariant, with respect to the positioning
of key residues and the face of bound NADPH, which
is exposed to substrate, and this hypothesis is strongly
supported by our homology modeling experiments
and those of Reid et al. [22]. The differences in
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(A–D) The products of ketoreduction of (2R, S)-2-methyl-3-oxopentanoic acid NAC ester 1 were separated on a Chiracel OD chiral HPLC
column after incubation with (A) wild-type eryKR1, (B) KR1-WGG, (C) KR1-PQS, or (D) KR1-WGG/PQS (also referred to in the text as KR1-5M).stereochemical outcome between A-type and B-type
KR domains would then arise because the entering sub-
strate has available two alternative binding modes, re-
lated by a 180º rotation about the axis of the target car-
bonyl group, and the residues of motifs I and II affect the
energetic balance between the two. We currently favor
this model, which also accounts for the range of kinetic
and stereochemical behavior seen with diketide sub-
strates on different recombinant KR domains [19].
Configurational Switching
in Polyketide Biosynthesis
The stereochemistry of ketoreduction in polyketide bio-
synthesis is tightly controlled in nature by KR domains.
Previous efforts to harness the intrinsic stereospecificity
of KR domains have involved the replacement of an en-
tire KR domain by another one of opposite stereochem-
istry within a PKS multienzyme ([14] and J.L. Kellen-
berger and P.F.L., unpublished data). Although some
of these chimeric constructs generated the product
with altered alcohol (C-3) stereochemistry, the yields
of the desired novel compound were relatively low.
One plausible explanation for the mixed success of do-
main-swap (or module-swap) strategies is that swap-ping a KR domain for another from a different natural
modular PKS not only could alter the stereochemistry
at the site of reduction, but might also reduce the overall
activity of the PKS, through the introduction of unfavor-
able protein:protein interactions. Reid et al. have previ-
ously demonstrated that ablation of KR activity in exten-
sion module 6 of the erythromycin-producing PKS by
site-specific change of the essential tyrosine residue
gave a slightly better yield of macrocyclic oxolactone
product, both in vivo and in vitro, than when the engi-
neering was done by a domain swap [22]. In this paper,
we have identified several amino acids in eryKR1 that,
when changed simultaneously, allow it to retain its activ-
ity but actually switch its intrinsic stereospecificity. Pre-
viously, two groups have reported independently that
site-directed mutagenesis of PKS AT domains led to
a relaxation of extender unit specificity, falling short of
a complete switch [30, 31]. If a PKS multienzyme with
such KR active site substitutions generated novel com-
pounds efficiently and with specifically altered configu-
ration, it would offer an attractive additional route to en-
gineered polyketides. Clearly, to make the best use of
the strategy, we need to know far more about how
changes in nonessential KR active site residues affect
Mutagenesis of Modular PKS Ketoreductases
283Figure 6. Stereochemical Outcome of Reduction by Wild-Type and Mutant eryKR2 Domains
(A–C) The products of ketoreduction of (2R, S)-2-methyl-3-oxopentanoic acid NAC ester 1 were separated on a Chiracel OD chiral HPLC col-
umn after incubation with (A) wild-type eryKR2, (B) KR2-LDD, or (C) KR2-LDD/LPN (also referred to in the text as KR2-6M).
(D) The separation of a mixture of synthetic standards is also shown.activity and stereoselectivity. In the accompanying pa-
per [24], we demonstrate how high-throughput muta-
genesis of isolated KR domains can be used rapidly to
explore the effects of replacing such residues, and to
develop a more detailed model for stereochemical con-
trol in these enzymes.
Significance
Attempts to alter the configuration at specific stereo-
centers in polyketide natural products by engineering
the biosynthetic genes have been hampered by a lim-
ited understanding of the fundamental mechanisms
by which modular polyketide synthases (PKSs) exert
stereocontrol over polyketide assembly. Previous
work has indicated that ketoreductase (KR) domains
exercise control over the configuration of the alcohol
product by favoring one of two alternative modes of
binding of the 3-oxoacyl substrate, and empirical cor-
relations have been detected between the presence of
certain amino acid sequence motifs in natural PKS KR
domains and the stereoselectivity of the reduction.
Here, we have used homology modeling to confirm
that these sequence motifs are at the KR active site,
where they might interact directly with bound sub-
strate. In one case, the substitution of two of these
amino acid residues gave a mutant enzyme with re-
duced activity, but with a switch in the configuration
of the alcohol product. Optimization of this approach,and its extension to KR domains within intact PKS
multienzymes, could lead to more reliable and efficient
engineering of polyketide stereochemistry, with po-
tentially wide-ranging benefits for rationally engi-
neered biosynthesis of polyketide therapeutics.
Experimental Procedures
Materials
Routine cloning and transformation procedures were as previously
described for E. coli [32]. Electrocompetent cells of the E. coli
DH10B strain were made as described previously [33]. All antibiotics
were bought from Sigma. PCR reactions were performed on a pro-
grammable Robo Cycler Gradient 96 (Stratagene). Automated DNA
sequencing was carried out on double-stranded DNA templates
by using an automated ABI Prism 3700 DNA Analyzer (Applied Bio-
systems). LB medium contained 10 g tryptone (Duchefa), 5 g yeast
extract (Duchefa), and 10 g NaCl in 1 liter of water.
Cloning Procedures
The plasmid used as a template for site-directed mutagenesis of
eryKR1 was pAPS28 [19], which contains the DNA encoding the
eryKR1 domain (plus flanking regions) cloned into the expression
vector pGEX-4T-3 (Stratagene) to create a C-terminal fusion protein
with glutathione-S-transferase (GST) [19]. The corresponding plas-
mid used as a template for mutagenesis of eryKR2 was pVS1, which
likewise contains the DNA encoding the eryKR2 domain (plus flank-
ing regions) cloned into the expression vector pGEX-4T-3 (Strata-
gene) [19]. Mutagenesis was carried out by overlap PCR by using
Pfu DNA polymerase (Stratagene) and specific mutagenic oligonu-
cleotides in two separate PCR reactions, as detailed in Table S1
(see the Supplemental Data available with this article online). The
PCR products from reactions 1 and 2 were mixed together and
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284used as a template for a third PCR reaction by using the appropriate
flanking primers. The resulting fragment was in each case a full-
length KR domain that contained the desired mutations. These frag-
ments were digested with BamHI and EcoRI and cloned into expres-
sion plasmid pGEX-4T-3, previously cut with the same enzymes. The
KR1 mutant with five substitutions across both motifs I and II, and
the KR2 mutant with six substitutions across motifs I and II (Figure 3),
were made by substituting the StyI/EcoRI fragment from eryKR1-
WGG and eryKR2-LPN into the corresponding unique sites of
the eryKR1-PQS and eryKR2-LDD, respectively, resulting in the
eryKR1-PQS-WGG (eryKR1-5M) and eryKR2-LDD-LPN (eryKR2-6M)
housed in the pGEX expression vector. All constructs were verified
by DNA sequencing.
Protein Expression
One liter of culture in LB medium of E. coli-BL21(DE3)-CodonPlus-
RP (Stratagene) harboring the recombinant plasmids was grown at
30ºC to an OD600 of 0.4, under carbenicillin (50 mg/ml) and chloram-
phenicol (34 mg/ml) selection. The cultures were cooled to 22ºC and,
upon reaching an A600 of 0.6, induced with 0.1 mM IPTG (Melford
Laboratories); the cell growth continued for 16 hr. Cells were har-
vested by centrifugation, and cell pellets were stored at 220ºC.
Protein Purification
Typically, frozen cell pellets (about 3 g wet weight) were thawed and
resuspended in 20 ml lysis buffer (100 mM NaH2PO4 [pH 8.2],
150 mM NaCl, 1 mM dithiothreitol, 10% glycerol) containing 1 tablet
of protease inhibitors (Complete Roche, Indianapolis, IN) per 25 ml,
RNase (25 mg/l, Sigma), DNase (100 mg/l, Sigma), and lysozyme
(1 mg/ml, Sigma). The cell suspensions were incubated on ice for
40 min and disrupted by passage through a French pressure cell
(SLM Instruments, Urbana, IL) operated at 1000 psi, and the insolu-
ble material was collected by centrifugation. The resulting superna-
tant was applied to a 50% suspension of glutathione-agarose beads
(Sigma), prepared according to the manufacturer’s instructions, and
incubated for 45 min at 4ºC. The beads were washed several times
by resuspending in 10 volumes of 25 mM HEPES-KOH buffer (pH
7.5) containing 150 mM NaCl, and eluted with the same buffer con-
taining 20 mM reduced glutathione. The elution step was repeated
three times, and the fractions collected. The combined protein-con-
taining fractions were concentrated in a spin concentrator to a final
volume of 2.5 ml, and the glutathione was removed by using a PD10
(Pharmacia) column equilibrated with 25 mM HEPES-KOH buffer (pH
7.5), containing 150 mM NaCl. Typical yields for all proteins were 6–
10 mg/l of culture, as measured by the bicinchoninic acid (BCA) as-
say (Pierce, Rockford, IL).
Kinetic Assays
NADPH-linked assays were carried out at 30ºC in the chamber of
a Spectramax Plus 96-well microplate reader equipped with Soft-
max Pro data acquisition software (Molecular Devices, Sunnyvale,
CA). The reactions were followed by monitoring the change in absor-
bance at 340 nm at 30 s intervals for 7 min in a UV transparent 96-well
plate (Greiner Bio-One, Kremsmuenster, Austria). Protein samples
(0.1–0.3 mg/ml) were incubated with saturating amounts of cofactor
and substrate (1.0 mM NADPH, 30 mM (2R, S)-2-methyl-3-oxopen-
tanoic acid N-acetylcysteamine thioester 1) in 400 mM potassium
phosphate buffer (pH 7.5) at 30ºC. Protein concentration was deter-
mined after the assay by the BCA method. The total assay volume
was 200 ml. The enzyme was preincubated with NADPH for 20 min,
the substrate was added, and the reaction was mixed by shaking
for 10 s before taking the first reading, and for 3 s prior to each sub-
sequent reading. All readings were corrected for the change in ab-
sorbance at 340 nm in the absence of enzyme, and each assay
was repeated in triplicate.
Product Separation by Chiral HPLC
Reduction of (2R, S)-2-methyl-3-oxopentanoic acid N-acetylcyste-
amine thioester 1 was carried out in a total volume of 200 ml contain-
ing 10 mM NADPH, 15 mM 1, 200 mM NaH2PO4 (pH 7.5), and either
wild-type (0.1 mg/ml, 2 mM) or mutant (1.0 mg/ml, 20 mM) KR en-
zymes. Reactions were incubated at 22ºC for 16 hr and extracted
with 3 ml ethyl acetate. Extracts were evaporated and resuspended
in 50 ml isopropanol. The reaction products were separated witha ChiraCel OC column (Daicel, 25 cm 3 4.6 mm), connected to an
Agilent HPLC system at a flow rate of 0.8 ml/min in an isocratic
mobile phase of 93% isohexane/7% ethanol at 40ºC for 2 hr. The
unreacted 1 still present served as an internal standard for the cali-
bration of traces. Control samples were run with each batch of anal-
yses to determine the retention times of the four diastereoisomeric
products 2–5 (Figure 6D). Additionally, some samples were spiked
with one of the standards to aid identification.
Homology Modeling of the KR1 and KR2 Structures
The sequences of erythromycin PKS ketoreductase 1 and 2 (eryKR1
and eryKR2) were compared with all protein sequences deposited in
SWISS-PROT, by using the Blast v2.2 program [34]. A PSI-BLAST
search in each case produced an alignment between the eryKR do-
main and homologous proteins, which highlighted conserved resi-
dues in the short-chain dehydrogenase/reductase (SDR) family to
which the eryKR domains were found to belong, as previously re-
ported [22]. Homologous proteins with known structure were identi-
fied by using the FUGUE [35] homology recognition server. FUGUE
searches for homologs in the structural profile library derived from
the structure-based alignments in the HOMSTRAD database [35]
and uses the environment-specific substitution tables to generate,
automatically, the best alignments for the top hits. The homolog
found with the highest percentage of identity (28%) to both eryKR
domains was porcine carbonyl reductase (pdb code: 1N5D). The
alignments produced by FUGUE for this highest-scoring hit were
formatted with JOY [36] and analyzed visually to highlight the con-
servation of structurally and functionally important residues. The
alignment was further improved by using SEAVIEW [37]. The models
of eryKR1 and eryKR2 were constructed with MODELLER [38] by us-
ing porcine carbonyl reductase as the template. The models were
improved by using the loop-building programs RAPPER [39] and
CODA [40]. Final energy and structure minimization were performed
by using the SYBYL (Tripos, Inc., St. Louis, MO, USA) force field. Fi-
nally, the models were validated by PROCHECK [41], VERIFY3D [42],
and by visual inspection with 3D graphics software. The results from
all of these programs revealed that the models did not require further
modification.
Supplemental Data
Supplemental Data including the methods used to construct the ho-
mology models and the sequences of oligonucleotide primers used
for mutagenesis are available at http://www.chembiol.com/cgi/
content/full/13/3/277/DC1/.
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